S. erythraea NRRL23338 electron micrograph by Jeremy Skepper
Courtesy of Jeremy Skepper, electron micrograph of S. erythraea mycelium growing on 2TY medium agar.

Introduction

Saccharopolyspora erythraea is the filamentous soil microbe, used for the industrial-scale production of the antibiotic erythromycin A, derivatives of which play a vital role in medicine. Here we present the complete genome sequence and annotation of the chromosome of this organism and the tools for viewing genome annotation data. The sequenced chromosome of this soil bacterium comprises 8,212,805 base pairs, predicted to encode 7,264 genes. It is circular, like those of the pathogenic actinomycetes Mycobacterium tuberculosis and Corynebacterium diphtheriae, but unlike the linear chromosomes of the model actinomycete Streptomyces coelicolor A3(2) and the closely related Streptomyces avermitilis. The S. erythraea genome contains at least 25 gene clusters for production of known or predicted secondary metabolites, at least 72 genes predicted to confer resistance to a range of common antibiotic classes and many sets of duplicated genes to support its saprophytic lifestyle. The availability of the genome sequence of S. erythraea will improve insight into its biology and facilitate rational development of strains to generate high-titre producers of clinically important antibiotics.

Purpose

This web site was created to keep you up to date with the progress of the S. erythraea Genome Sequencing and Analysis Project and bring you the most recent findings as they come out. Data updates, search results, new genes and maps are going to be announced here.

Updates

The site will be updated regularly, at least once per week. Feel free to revisit! :^)

Your input needed

I would greatly appreciate any comments, suggestions and additions to make this site really useful to all of us.

All the data on this site are the result of a research effort of a team at the DNA Sequencing Facility, Department of Biochemistry, Cambridge, UK) in conjunction with Prof. Peter Leadlay.